{"id":49904,"date":"2022-10-21T13:01:53","date_gmt":"2022-10-21T11:01:53","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/lantern-pharma-to-present-at-the-thinkequity-conference-on-wednesday-october-26-at-100-p-m-et\/"},"modified":"2022-10-21T13:01:53","modified_gmt":"2022-10-21T11:01:53","slug":"lantern-pharma-to-present-at-the-thinkequity-conference-on-wednesday-october-26-at-100-p-m-et","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/lantern-pharma-to-present-at-the-thinkequity-conference-on-wednesday-october-26-at-100-p-m-et\/","title":{"rendered":"Lantern Pharma to Present at the ThinkEquity Conference on Wednesday, October 26 at 1:00 p.m. ET"},"content":{"rendered":"<div>\n<p>DALLAS&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/search?q=%24LTRN&amp;src=ctag\" target=\"_blank\" rel=\"noopener\">$LTRN<\/a>&#8211;Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR<sup>\u00ae<\/sup> artificial intelligence (&#8220;A.I.&#8221;) and machine learning (\u201cM.L.\u201d) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern management will be presenting at the ThinkEquity Conference, which is being held on October 26<sup>th<\/sup>, 2022 in New York, NY.\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nPanna Sharma, Lantern\u2019s CEO &amp; President, will be hosting an A.I. and Drug Development Panel at 10:00 a.m. ET focused on how A.I. is transforming the cost, pace, and risks involved in developing a new drug.<\/p>\n<p>Panelists will include noted experts from Weill Cornell, Volastra Therapeutics, InveniAI, and Hepion Pharmaceuticals.\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\nLantern Pharma is scheduled to present at the conference on Wednesday, October 26<sup>th<\/sup> at 1:00 p.m. ET.<br \/>\n<br \/><b>Webcast Link<\/b>: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwsw.com%2Fwebcast%2Ftep23%2Fltrn%2F1697728&amp;esheet=52949587&amp;newsitemid=20221021005040&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwsw.com%2Fwebcast%2Ftep23%2Fltrn%2F1697728&amp;index=1&amp;md5=494fe53261c8895e5adf68dfa1f3c5a4\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/wsw.com\/webcast\/tep23\/ltrn\/1697728<\/a><br \/><b>Registration Link<\/b>: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.meetmax.com%2Fsched%2Fevent_84407%2Fconference_register.html&amp;esheet=52949587&amp;newsitemid=20221021005040&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.meetmax.com%2Fsched%2Fevent_84407%2Fconference_register.html&amp;index=2&amp;md5=0c5f6168c3a8d8c1d2e1ec44a5d18b24\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.meetmax.com\/sched\/event_84407\/conference_register.html<\/a>\n<\/li>\n<\/ul>\n<p>\nLantern Pharma management will be available for one-on-one meetings to be held throughout the conference.\n<\/p>\n<p>\n<b>About Lantern Pharma:<\/b>\n<\/p>\n<p>\nLantern Pharma (NASDAQ: LTRN) is a clinical-stage oncology-focused biopharmaceutical company leveraging its proprietary RADR<sup>\u00ae<\/sup> A.I. and machine learning platform to discover biomarker signatures that identify patients most likely to respond to its pipeline of genomically-targeted therapeutics. Lantern is currently developing four drug candidates and an ADC program across nine disclosed tumor targets, including two phase 2 programs. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, Lantern&#8217;s approach represents the potential to deliver best-in-class outcomes.\n<\/p>\n<p>\nPlease find more information at:<br \/>\n<br \/>Website: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lanternpharma.com&amp;esheet=52949587&amp;newsitemid=20221021005040&amp;lan=en-US&amp;anchor=www.lanternpharma.com&amp;index=3&amp;md5=1dbe9bdb4800e7d1cff5aa6219be8568\" rel=\"nofollow noopener\" shape=\"rect\">www.lanternpharma.com<\/a><br \/>LinkedIn: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Flanternpharma%2F&amp;esheet=52949587&amp;newsitemid=20221021005040&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Flanternpharma%2F&amp;index=4&amp;md5=dd6303ab466298d97229f8594888fbee\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.linkedin.com\/company\/lanternpharma\/<\/a><br \/>Twitter: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FLanternPharma&amp;esheet=52949587&amp;newsitemid=20221021005040&amp;lan=en-US&amp;anchor=%40lanternpharma&amp;index=5&amp;md5=6a557d114a14ef4235ada87af2ad2ce5\" rel=\"nofollow noopener\" shape=\"rect\">@lanternpharma<\/a>\n<\/p>\n<p>\n<b>Forward-looking Statements:<\/b>\n<\/p>\n<p>\nThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR\u00ae platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR\u00ae platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;seek,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;objective,&#8221; &#8220;aim,&#8221; &#8220;upcoming,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the impact of the COVID-19 pandemic, (ii) the risk that our research and the research of our collaborators may not be successful, (iii) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (iv) the risk that no drug product based on our proprietary RADR\u00ae A.I. platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (v) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 10, 2022. You may access our Annual Report on Form 10-K for the year ended December 31, 2021 under the investor SEC filings tab of our website at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lanternpharma.com%2F&amp;esheet=52949587&amp;newsitemid=20221021005040&amp;lan=en-US&amp;anchor=www.lanternpharma.com&amp;index=6&amp;md5=072b61eac4ab36b5530be1b618aeec7e\" rel=\"nofollow noopener\" shape=\"rect\">www.lanternpharma.com<\/a> or on the SEC&#8217;s website at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=52949587&amp;newsitemid=20221021005040&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=5d5656ece89daa4381c0d1f84090fce3\" rel=\"nofollow noopener\" shape=\"rect\">www.sec.gov<\/a>. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nNicole Leber<br \/>\n<br \/>Investor Relations Associate<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#x6f;&#x3a;&#105;&#114;&#64;&#108;&#97;nter&#x6e;&#x70;&#x68;&#x61;&#x72;&#x6d;&#x61;&#x2e;&#99;&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x69;&#x72;&#x40;&#x6c;&#x61;&#x6e;&#116;&#101;&#114;&#110;phar&#x6d;&#x61;&#x2e;&#x63;&#x6f;&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DALLAS&#8211;(BUSINESS WIRE)&#8211;$LTRN&#8211;Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR\u00ae artificial intelligence (&#8220;A.I.&#8221;) and machine learning (\u201cM.L.\u201d) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern management will be presenting at the ThinkEquity Conference, which is being held on October 26th, &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/lantern-pharma-to-present-at-the-thinkequity-conference-on-wednesday-october-26-at-100-p-m-et\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49904","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lantern Pharma to Present at the ThinkEquity Conference on Wednesday, October 26 at 1:00 p.m. ET - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/lantern-pharma-to-present-at-the-thinkequity-conference-on-wednesday-october-26-at-100-p-m-et\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lantern Pharma to Present at the ThinkEquity Conference on Wednesday, October 26 at 1:00 p.m. ET - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DALLAS&#8211;(BUSINESS WIRE)&#8211;$LTRN&#8211;Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR\u00ae artificial intelligence (&#8220;A.I.&#8221;) and machine learning (\u201cM.L.\u201d) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern management will be presenting at the ThinkEquity Conference, which is being held on October 26th, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/lantern-pharma-to-present-at-the-thinkequity-conference-on-wednesday-october-26-at-100-p-m-et\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-21T11:01:53+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lantern-pharma-to-present-at-the-thinkequity-conference-on-wednesday-october-26-at-100-p-m-et\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lantern-pharma-to-present-at-the-thinkequity-conference-on-wednesday-october-26-at-100-p-m-et\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Lantern Pharma to Present at the ThinkEquity Conference on Wednesday, October 26 at 1:00 p.m. ET\",\"datePublished\":\"2022-10-21T11:01:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lantern-pharma-to-present-at-the-thinkequity-conference-on-wednesday-october-26-at-100-p-m-et\\\/\"},\"wordCount\":847,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lantern-pharma-to-present-at-the-thinkequity-conference-on-wednesday-october-26-at-100-p-m-et\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lantern-pharma-to-present-at-the-thinkequity-conference-on-wednesday-october-26-at-100-p-m-et\\\/\",\"name\":\"Lantern Pharma to Present at the ThinkEquity Conference on Wednesday, October 26 at 1:00 p.m. ET - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-10-21T11:01:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lantern-pharma-to-present-at-the-thinkequity-conference-on-wednesday-october-26-at-100-p-m-et\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lantern-pharma-to-present-at-the-thinkequity-conference-on-wednesday-october-26-at-100-p-m-et\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lantern-pharma-to-present-at-the-thinkequity-conference-on-wednesday-october-26-at-100-p-m-et\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lantern Pharma to Present at the ThinkEquity Conference on Wednesday, October 26 at 1:00 p.m. ET\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lantern Pharma to Present at the ThinkEquity Conference on Wednesday, October 26 at 1:00 p.m. ET - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/lantern-pharma-to-present-at-the-thinkequity-conference-on-wednesday-october-26-at-100-p-m-et\/","og_locale":"en_US","og_type":"article","og_title":"Lantern Pharma to Present at the ThinkEquity Conference on Wednesday, October 26 at 1:00 p.m. ET - Pharma Trend","og_description":"DALLAS&#8211;(BUSINESS WIRE)&#8211;$LTRN&#8211;Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR\u00ae artificial intelligence (&#8220;A.I.&#8221;) and machine learning (\u201cM.L.\u201d) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern management will be presenting at the ThinkEquity Conference, which is being held on October 26th, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/lantern-pharma-to-present-at-the-thinkequity-conference-on-wednesday-october-26-at-100-p-m-et\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-21T11:01:53+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/lantern-pharma-to-present-at-the-thinkequity-conference-on-wednesday-october-26-at-100-p-m-et\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/lantern-pharma-to-present-at-the-thinkequity-conference-on-wednesday-october-26-at-100-p-m-et\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Lantern Pharma to Present at the ThinkEquity Conference on Wednesday, October 26 at 1:00 p.m. ET","datePublished":"2022-10-21T11:01:53+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/lantern-pharma-to-present-at-the-thinkequity-conference-on-wednesday-october-26-at-100-p-m-et\/"},"wordCount":847,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/lantern-pharma-to-present-at-the-thinkequity-conference-on-wednesday-october-26-at-100-p-m-et\/","url":"https:\/\/pharma-trend.com\/en\/lantern-pharma-to-present-at-the-thinkequity-conference-on-wednesday-october-26-at-100-p-m-et\/","name":"Lantern Pharma to Present at the ThinkEquity Conference on Wednesday, October 26 at 1:00 p.m. ET - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-10-21T11:01:53+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/lantern-pharma-to-present-at-the-thinkequity-conference-on-wednesday-october-26-at-100-p-m-et\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/lantern-pharma-to-present-at-the-thinkequity-conference-on-wednesday-october-26-at-100-p-m-et\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/lantern-pharma-to-present-at-the-thinkequity-conference-on-wednesday-october-26-at-100-p-m-et\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Lantern Pharma to Present at the ThinkEquity Conference on Wednesday, October 26 at 1:00 p.m. ET"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49904","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49904"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49904\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49904"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49904"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49904"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}